These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 33105713)

  • 1. The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer.
    Turnham DJ; Bullock N; Dass MS; Staffurth JN; Pearson HB
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer, PI3K, PTEN and prognosis.
    Wise HM; Hermida MA; Leslie NR
    Clin Sci (Lond); 2017 Feb; 131(3):197-210. PubMed ID: 28057891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way.
    Zhang X; Wang D; Liu B; Jin X; Wang X; Pan J; Tu W; Shao Y
    J Exp Clin Cancer Res; 2020 Sep; 39(1):190. PubMed ID: 32938489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
    Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
    Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.
    Choudhury AD
    Prostate; 2022 Aug; 82 Suppl 1():S60-S72. PubMed ID: 35657152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
    Braglia L; Zavatti M; Vinceti M; Martelli AM; Marmiroli S
    Biochim Biophys Acta Mol Cell Res; 2020 Sep; 1867(9):118731. PubMed ID: 32360668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
    Pungsrinont T; Kallenbach J; Baniahmad A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.
    Ferraldeschi R; Nava Rodrigues D; Riisnaes R; Miranda S; Figueiredo I; Rescigno P; Ravi P; Pezaro C; Omlin A; Lorente D; Zafeiriou Z; Mateo J; Altavilla A; Sideris S; Bianchini D; Grist E; Thway K; Perez Lopez R; Tunariu N; Parker C; Dearnaley D; Reid A; Attard G; de Bono J
    Eur Urol; 2015 Apr; 67(4):795-802. PubMed ID: 25454616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
    Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
    BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer.
    Nip H; Dar AA; Saini S; Colden M; Varahram S; Chowdhary H; Yamamura S; Mitsui Y; Tanaka Y; Kato T; Hashimoto Y; Shiina M; Kulkarni P; Dasgupta P; Imai-Sumida M; Tabatabai ZL; Greene K; Deng G; Dahiya R; Majid S
    Oncotarget; 2016 Oct; 7(42):68371-68384. PubMed ID: 27634912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
    De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
    Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of PTEN loss in prostate cancer.
    Jamaspishvili T; Berman DM; Ross AE; Scher HI; De Marzo AM; Squire JA; Lotan TL
    Nat Rev Urol; 2018 Apr; 15(4):222-234. PubMed ID: 29460925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP.
    Kim S; Huang W; Mottillo EP; Sohail A; Ham YA; Conley-Lacomb MK; Kim CJ; Tzivion G; Kim HR; Wang S; Chen YQ; Fridman R
    Biochim Biophys Acta; 2010 Nov; 1803(11):1287-97. PubMed ID: 20620173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AKT and cytosolic phospholipase A2α form a positive loop in prostate cancer cells.
    Hua S; Vignarajan S; Yao M; Xie C; Sved P; Dong Q
    Curr Cancer Drug Targets; 2015; 15(9):781-91. PubMed ID: 26143945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NOTCH and PTEN in prostate cancer.
    Bertrand FE; McCubrey JA; Angus CW; Nutter JM; Sigounas G
    Adv Biol Regul; 2014 Sep; 56():51-65. PubMed ID: 24933481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting.
    Ciuffreda L; Falcone I; Incani UC; Del Curatolo A; Conciatori F; Matteoni S; Vari S; Vaccaro V; Cognetti F; Milella M
    Adv Biol Regul; 2014 Sep; 56():66-80. PubMed ID: 25088603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.